Oxford University, Serum Institute of India tie-up delivers 'high efficacy' malaria vaccine

The R21/Matrix-M vaccine, leveraging Novavax's adjuvant technology, has been approved for use in children aged 5 to 36 months - the age group at the highest risk of death from malaria. It marks the first regulatory clearance for the R21/Matrix-M malaria vaccine for use in any country.
Source: The Economic Times - Category: Consumer Health News Source Type: news